# Reborna Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/reborna-biosciences

- Industry: Biotechnology
- Headquarters: Fujisawa-shi, Japan
- Website: www.rebornabiosciences.com
- Total disclosed funding: $7.1M
- Latest round: Series D (May 25, 2023)
- Investors on record: 6

## About

Reborna Biosciences, Inc., based in Fujisawa-shi, Japan, specializes in developing therapies for genetic rare diseases using innovative drug discovery technology to create low molecular weight drugs that target RNA functionalities.Founded in 2018 in Fujisawa-shi, Japan, Reborna Biosciences, Inc. is focused on innovative therapeutics for rare genetic conditions. The company has completed 2 funding deals, with the most recent being a Series D round on May 25, 2023, raising JPY 670 million. Nissay Capital led this round, with participation from Angel Bridge, Shionogi Pharmaceutical, and Toho Holdings. As of this latest round, the total amount raised stands at JPY 670 million, with a current company valuation of JPY 1,670.588 million.Reborna Biosciences, Inc. specializes in the development of innovative therapies targeting genetic rare diseases through its unique drug discovery technology that focuses on low molecular weight drugs with high affinity for ribonucleic acid (RNA). This approach aims to create therapeutics that normalize RNA function, addressing unmet medical needs in conditions often caused by hereditary genetic mutations. The company’s pipeline includes orally administered drugs designed to ease the burden of long-term treatment for patients, thereby improving their quality of life. Reborna's client base primarily consists of healthcare providers and research institutions focused on rare genetic disorders, while end users are patients suffering from these conditions and their families. Its products are aimed at markets in North America, Europe, and parts of Asia, reflecting a strategic focus on regions with high demand for innovative healthcare solutions.Reborna Biosciences generates revenue through strategic partnerships and collaborations with healthcare organizations and pharmaceutical companies involved in the treatment of rare diseases. Transactions typically involve B2B agreements where Reborna provides its proprietary drug development services in exchange for milestone payments and royalties based on product commercialization. The revenue structure may include phased payments linked to research and development milestones, as well as ongoing royalties from the sale of therapeutics once they reach the market. The company’s flagship products are positioned as high-value innovations in the biopharmaceutical space, designed specifically for genetic disorders, which contributes to a comprehensive approach to addressing complex healthcare challenges.In May 2023, Reborna Biosciences, Inc. successfully raised JPY 670 million in Series D funding. This investment will enable the company to accelerate the research and development of its pipeline and further enhance its platform. Plans include the development of new therapeutics targeting genetic disorders and expanding into markets across North America, Europe, and parts of Asia by 2024. The recent funding will support these initiatives, ensuring that Reborna remains at the forefront of innovation in treating rare diseases.

## Funding rounds

- Series D, May 25, 2023, $4.8M — Shionogi Pharmaceutical, Nissay Capital, Toho Holdings, Angel Bridge
- Seed, Jun 25, 2018, $2.3M — Mitsubishi UFJ Capital, Takeda Pharmaceutical

## Investors

- Mitsubishi UFJ Capital (https://capitalatlas.ai/funds/mitsubishi-ufj-capital) — Seed
- Takeda Pharmaceutical — Seed
- Shionogi Pharmaceutical — Series D
- Nissay Capital (https://capitalatlas.ai/funds/nissay-capital) — Series D
- Toho Holdings — Series D
- Angel Bridge (https://capitalatlas.ai/funds/angel-bridge) — Series D